A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Atezolizumab (Primary) ; MOXR 0916 (Primary) ; Bevacizumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 22 Aug 2017 Planned End Date changed from 29 Dec 2018 to 12 Aug 2018.
- 22 Aug 2017 Planned primary completion date changed from 29 Dec 2018 to 12 Aug 2018.
- 06 Jul 2017 Planned number of patients changed from 762 to 610.